Literature DB >> 26488814

Tumor Microenvironment and Immunotherapy: The Whole Picture Is Better Than a Glimpse.

Sarah E Church1, Jérôme Galon2.   

Abstract

Predicting cancer patients' response to therapy is essential for curing disease and improving quality of life. Garraway and colleagues demonstrate that the frequency and number of neoantigens, non-synonymous mutations, and adaptive immune genes, but not the assessment of individual recurrent neoantigens or mutations, predicts patient responses to immunotherapy.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26488814     DOI： 10.1016/j.immuni.2015.10.004

Source DB:  PubMed          Journal:  Immunity        ISSN： 1074-7613            Impact factor:   31.745


  19 in total

Review 1.  Integrative Pharmacology: Advancing Development of Effective Immunotherapies.

Authors:  Mohammad Tabrizi; Daping Zhang; Vaishnavi Ganti; Glareh Azadi
Journal:  AAPS J       Date:  2018-04-27       Impact factor: 4.009

Review 2.  Immunological battlefield in gastric cancer and role of immunotherapies.

Authors:  Minyu Wang; Rita A Busuttil; Sharon Pattison; Paul J Neeson; Alex Boussioutas
Journal:  World J Gastroenterol       Date:  2016-07-28       Impact factor: 5.742

3.  The DNA Methylcytosine Dioxygenase Tet2 Sustains Immunosuppressive Function of Tumor-Infiltrating Myeloid Cells to Promote Melanoma Progression.

Authors:  Wen Pan; Shu Zhu; Kun Qu; Katrina Meeth; Jijun Cheng; Kaixin He; Hongdi Ma; Yan Liao; Xizhi Wen; Christine Roden; Zuzana Tobiasova; Zheng Wei; Jun Zhao; Jun Liu; Ji Zheng; Bo Guo; Sajid A Khan; Marcus Bosenberg; Richard A Flavell; Jun Lu
Journal:  Immunity       Date:  2017-08-15       Impact factor: 31.745

4.  The oncolytic peptide LTX-315 overcomes resistance of cancers to immunotherapy with CTLA4 checkpoint blockade.

Authors:  T Yamazaki; J M Pitt; M Vétizou; A Marabelle; C Flores; Ø Rekdal; G Kroemer; L Zitvogel
Journal:  Cell Death Differ       Date:  2016-04-15       Impact factor: 15.828

5.  Peripheral blood Th9 cells are a possible pharmacodynamic biomarker of nivolumab treatment efficacy in metastatic melanoma patients.

Authors:  Yumi Nonomura; Atsushi Otsuka; Chisa Nakashima; Judith A Seidel; Akihiko Kitoh; Teruki Dainichi; Saeko Nakajima; Yu Sawada; Shigeto Matsushita; Megumi Aoki; Tatsuya Takenouchi; Taku Fujimura; Naohito Hatta; Satoshi Koreeda; Satoshi Fukushima; Tetsuya Honda; Kenji Kabashima
Journal:  Oncoimmunology       Date:  2016-10-18       Impact factor: 8.110

6.  Nanoparticle-Mediated Trapping of Wnt Family Member 5A in Tumor Microenvironments Enhances Immunotherapy for B-Raf Proto-Oncogene Mutant Melanoma.

Authors:  Qi Liu; Hongda Zhu; Karthik Tiruthani; Limei Shen; Fengqian Chen; Keliang Gao; Xueqiong Zhang; Lin Hou; Degeng Wang; Rihe Liu; Leaf Huang
Journal:  ACS Nano       Date:  2018-01-31       Impact factor: 15.881

Review 7.  The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy.

Authors:  Daniela Bruni; Helen K Angell; Jérôme Galon
Journal:  Nat Rev Cancer       Date:  2020-08-04       Impact factor: 60.716

Review 8.  The application of the fibroblast activation protein α-targeted immunotherapy strategy.

Authors:  Guan-Min Jiang; Wei Xu; Jun Du; Kun-Shui Zhang; Qiu-Gui Zhang; Xiao-Wei Wang; Zhi-Gang Liu; Shuang-Quan Liu; Wan-Ying Xie; Hui-Fang Liu; Jing-Shi Liu; Bai-Ping Wu
Journal:  Oncotarget       Date:  2016-05-31

Review 9.  Serum Cytokinome Profile Evaluation: A Tool to Define New Diagnostic and Prognostic Markers of Cancer Using Multiplexed Bead-Based Immunoassays.

Authors:  Francesca Capone; Eliana Guerriero; Angela Sorice; Giovanni Colonna; Gennaro Ciliberto; Susan Costantini
Journal:  Mediators Inflamm       Date:  2016-12-06       Impact factor: 4.711

Review 10.  Newly developed anti-angiogenic therapy in non-small cell lung cancer.

Authors:  Jingjing Qu; Yongchang Zhang; Xue Chen; Haiyan Yang; Chunhua Zhou; Nong Yang
Journal:  Oncotarget       Date:  2017-12-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.